LivaNova PLC (LIVN) stock
LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 13/3032% above fair value
$94.54+2.62 (+2.85%)
Close on Nov 18, 2026Market cap $5.21BP/E 27.9Yield –
LivaNova EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
LivaNova's EPS for the twelve months ending Jun 30, 2026 was $3.39. For fiscal 2025 it was -$4.45, down 483.6% from the year before. The highest annual figure on record is $2.17 in fiscal 2015.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.45 | -483.6% |
| FY2024 | Dec 31, 2024 | $1.16 | +262.5% |
| FY2023 | Dec 31, 2023 | $0.32 | – |
| FY2022 | Dec 31, 2022 | -$1.61 | – |
| FY2021 | Dec 31, 2021 | -$2.68 | – |
| FY2020 | Dec 31, 2020 | -$7.18 | – |
| FY2019 | Dec 31, 2019 | -$3.26 | – |
| FY2018 | Dec 31, 2018 | -$3.91 | – |
| FY2017 | Dec 31, 2017 | -$0.52 | -124.0% |
| FY2015 | Apr 24, 2015 | $2.17 | +8.5% |
| FY2014 | Apr 25, 2014 | $2.00 | +20.5% |
| FY2013 | Apr 26, 2013 | $1.66 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $1.93 | +286.0% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $0.40 | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $0.57 | -44.1% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $0.49 | -18.3% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $0.50 | +66.7% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$6.01 | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $1.02 | +240.0% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $0.60 | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $0.30 | +1400.0% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$0.78 | -657.1% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $0.30 | +900.0% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$0.14 | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $0.02 | -93.3% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $0.14 | +133.3% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $0.03 | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$2.01 | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $0.30 | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $0.06 | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$0.10 | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$0.84 | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$1.15 | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$0.63 | -184.0% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$5.78 | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$0.30 | -145.5% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$1.84 | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $0.75 | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$2.96 | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $0.66 | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$0.60 | -293.5% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$0.31 | -214.8% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$4.34 | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$0.15 | -126.3% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $0.31 | -68.4% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $0.27 | +17.4% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$2.32 | -680.0% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $0.57 | -8.1% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $0.98 | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $0.23 | – |
| Q4 FY2015CQ1 2015 | Apr 24, 2015 | $0.40 | – |
| Q3 FY2015CQ4 2014 | Jan 23, 2015 | $0.62 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?